All Clinical Trials

A listing of 23130 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors

NCT00029445

Recruiting

This study will collect white blood cells and plasma for research on how the immune system controls HIV infection. The immune system of a very small group of HIV-infected patients, called non-progressors, has been able to control HIV for long periods without antiretroviral therapy. Some immune system-related genes important for this control have been identified in these patients. This study will examine the contribution of HLA genes B\*57+, B\*27+ and A\*01+ to HIV disease in progressors and long-term non-progressors. (HLA type is a genetic marker of the immune system.) HIV-infected patients 18 years of age and older with HLA types B\*57+, B\*27+ and/or A\*01+ may be eligible for this study. Participants will undergo apheresis-a method for collecting larger quantities of certain blood components than can safely be collected through a simple blood draw-by one of the following two methods: * Automated pheresis - Blood is drawn through a needle placed in an arm vein and spun in a machine, separating the blood components. The white cells are extracted and the red cells, with or without plasma (liquid part of the blood), are re-infused into the donor through the same needle or a needle in the other arm. An anticoagulant (medication to prevent blood from clotting) is usually added to the blood while in the machine to prevent it from clotting during processing. * Manual pheresis - One unit (1 pint) of blood is drawn through a needle placed in an arm vein, similar to donating a pint of whole blood. The red blood cells, with or without plasma, are separated from the rest of the blood and re-infused to the donor through the same needle. Manual pheresis will be done only when a person s estimated total blood volume or red cell count is too low to safely permit removal of blood through a pheresis machine. An adult small in size or markedly anemic, for example, may fall into this category. Some of the blood collected through apheresis may be stored for future studies of HIV disease and immune function and for HLA testing, a genetic test of markers of the immune system. Some of the blood may be used to screen for different types of viral liver infections, such as hepatitis A, B, C, D, E, F, or G. Read Less

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

06/25/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: HIV

Learn More ›

Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes

NCT01200680

Recruiting

Background: Chordoma is a rare, slow growing, often fatal bone cancer derived from remnants of the embryonic notochord. It occurs mostly in the axial skeleton (skull base, vertebrae, sacrum and coccyx), is more frequent in males than females, and has a median age at diagnosis of 58.5 years, with a wide age range. This typically sporadic tumor is often advanced at presentation, and mortality is high due to local recurrence or distant metastases. The usual treatment is surgery, followed by adjuvant radiation therapy. Chemotherapy has not had a significant treatment role. Reports of a small number of families worldwide with two or more relatives with chordoma support a role for susceptibility genes in chordoma etiology. Recently we determined that duplications of the T gene co-segregated with disease in four multiplex chordoma families. The T gene encodes brachyury, a tissue-specific transcription factor that is expressed in notochord cells and is essential for formation and maintenance of the notochord. Some of the other chordoma families that we studied did not have T-gene duplications; the aggregation of chordomas in these families may result from changes in other susceptibility genes or other types of mutations targeting the T gene. We are continuing gene identification studies of multiplex chordoma families at the NIH Clinical Center under protocol 78-C-0039. We also want to determine whether alterations in any identified chordoma susceptibility genes are associated with sporadic chordoma in the general population. Objectives: The major goal of this protocol is to identify sporadic chordoma patients willing to provide germline and tumor DNA for studies to determine the frequency of alterations in chordoma susceptibility genes. Our previous protocols with SEER and Massachusetts General Hospital to identify chordoma patients were limited to residents of specific geographic regions in the U.S. (2 states and 2 metropolitan areas) or to patients with pediatric skull base tumors. This protocol will enroll patients who more broadly represent the age, site and gender distributions of sporadic chordoma in the general U.S. population. Eligibility: Eligible patients are males and females in the U.S. with chordoma diagnosed at any age and at any primary site. Because we want to obtain saliva from all participants, eligibility is limited to patients who will be greater than or equal to age 6 years at the time of enrollment. Design: The study description and contacting information including an e-mail link to the study contact person will be posted on web sites of two chordoma support groups. We will mail study information to be given to patients to colleagues at major medical centers that treat chordoma. The components of the study will be carried out in subjects' homes using materials mailed to them. Up to 100 participants will: 1) complete a self-administered Personal and Family Medical History Questionnaire, 2) collect saliva using a saliva collection kit, and 3) provide permission to obtain medical/pathology records, and paraffin blocks or slides on each primary chordoma. Parents will serve as proxies for minor children. We will recontact patients who report chordoma in at least one blood relative. If we confirm the relative's chordoma diagnosis, we will invite the study subject and selected family members to participate in clinical and gene mapping studies under protocol 78-C-0039. We may also recontact study participants to tell them about any new studies on chordoma etiology. They can decide at that time whether they want to participate in them. Read Less

Gender:

ALL

Ages:

6 years and above

Trial Updated:

06/25/2025

Locations: Westat, Inc., Rockville, Maryland

Conditions: Genes, Sporadic Chordoma

Learn More ›

Study of Treatment for HPV16+ ASC-US or LSIL

NCT03913117

Recruiting

Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine

Gender:

FEMALE

Ages:

19 years and above

Trial Updated:

06/25/2025

Locations: UAB | The University of Alabama at Birmingham, Birmingham, Alabama +1 locations

Conditions: ASC-US, LSIL

Learn More ›

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

NCT04616326

Recruiting

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.

Gender:

ALL

Ages:

Between 12 years and 17 years

Trial Updated:

06/25/2025

Locations: Rehabilitation & Neurological Services, Huntsville, Alabama +88 locations

Rehabilitation & Neurological Services, Huntsville, Alabama

21st Century Neurology, a Division of Xenoscience, Inc., Phoenix, Arizona

Phoenix Children's Hospital, Phoenix, Arizona

Center for Neurosciences, Tucson, Arizona

Miller Children's & Women's Hospital Long Beach, Long Beach, California

Children's Hospital Colorado, Aurora, Colorado

Northwest Florida Clinical Research Group, Gulf Breeze, Florida

Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville, Florida

Wellness Clinical Research, Miami Lakes, Florida

Vitaly Clinical Research, Miami, Florida

EMDA Clinical Research, Miami, Florida

Bio-Medical Research LLC, Miami, Florida

Allied Biomedical Research Institute, Miami, Florida

Ezy Medical Research, Miami, Florida

Avanza Medical Research Center, Pensacola, Florida

D&H Tamarac Research Center, Tamarac, Florida

Infinity Life Research Group, Tamarac, Florida

USF Health, Tampa, Florida

Palm Beach Research Center, West Palm Beach, Florida

Medical Research Partners, Ammon, Idaho

Northwest Clinical Trials, Boise, Idaho

St. Alexius Medical Center, Hoffman Estates, Illinois

Ascension Via Christi Research, Wichita, Kansas

University of Kentucky Chandler Medical Center, Lexington, Kentucky

Pharmasite Research, Inc., Baltimore, Maryland

MedVadis Research Corporation, Waltham, Massachusetts

Minneapolis Clinic of Neurology - Burnsville Office, Burnsville, Minnesota

Precise Research Centers, Flowood, Mississippi

Proven Endpoints, Ridgeland, Mississippi

Children Mercy Pediatric Clinical Research Unit, Kansas City, Missouri

Saint Peter's University Hospital, New Brunswick, New Jersey

Dent Neurologic Institute, Amherst, New York

Cohen Children's Northwell Health Physician Partners - Pediatric Neurology, New Hyde Park, New York

Velocity Clinical Research at Raleigh Neurology, Raleigh, North Carolina

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Headache Center of Hope, Cincinnati, Ohio

Providence Health & Services, Portland, Oregon

UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

Coastal Pediatric Research, Charleston, South Carolina

Access Clinical Trials - Nashville, Nashville, Tennessee

UT Southwestern Medical Center, Dallas, Texas

Prime Clinical Research - Lewisville, Lewisville, Texas

Medical Research Partners - Logan, Logan, Utah

Northwest Clinical Research Center, Bellevue, Washington

Seattle Children's Hospital, Seattle, Washington

Herlev and Gentofte Hospital, Copenhagen, Hovedstaden

Sanos Clinic - Nordjylland, Aalborg, Nordjylland

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone, Marseille, Bouches-du-Rhône

Bordeaux University Hospital - Pellegrin, Bordeaux, Gironde

Centre Hospitalier Régional Universitaire de Lille - Hôpital Roger Salengro, Lille, Nord-Pas-de-Calais

Centre Hospitalier Intercommunal de Créteil, Créteil, Paris

CHU d'Amiens-Picardie - Hôpital Sud, Amiens, Somme

Hôpital Armand Trousseau, Paris, Not set

Praxis Dr. Astrid Gendolla, Essen, Nordrhein-Westfalen

G.B. Pant Institute of Postgraduate Medical Education & Research, New Delhi, Delhi

Sir Ganga Ram Hospital, New Delhi, Delhi

Apollo Hospitals Ahmedabad, Ahmedabad, Gujarat

Artemis hospital, Gurugram, Haryana

Mangala Hospital & Mangala Kidney Foundation, Mangalore, Karnataka

Getwell Hospital and Research Institute, Nagpur, Maharashtra

Central India Cardiology and Research Institute, Nagpur, Maharashtra

Department of Pediatrics, Nagpur, Maharashtra

Medipoint Hospitals Pvt. Ltd., Pune, Maharashtra

Atmaram Child Care, Kanpur, Uttar Pradesh

Policlinico Umberto I, Roma, Lazio

IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia

Neuroscience, Roma, Not set

Konan Hospital, Kobe, Hyogo

Yamaguchi Clinic, Nishinomiya, Hyogo

Tokyo Medical University Hospital, Shinjuku-ku, Tokyo

Tanaka Neurosurgery&Headache Clinic, Kagoshima, Not set

Umenotsuji Clinic, Kochi, Not set

Tatsuoka Neurology Clinic, Kyoto, Not set

Tominaga Hospital, Osaka, Not set

Tokyo Headache Clinic, Tokyo, Not set

Hospital Infantil de Mexico Federico Gomez, Mexico City, Distrito Federal

Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco

PanAmerican Clinical Research - Guadalajara, Guadalajara, Jalisco

Clinica De Enfermedades Cronicas y Procedimientos Especiales, Morelia, Michoacan

Centro de Investigacion Medica Aguascalientes (CIMA), Aguascalientes, Not set

Unidad de Investigación en Salud, Chihuahua, Not set

Isala, locatie Zwolle, Zwolle, Overijssel

Ponce Medical School Foundation Inc., Ponce, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona [Barcelona]

Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona]

Hospital Clinico de Valencia, Valencia, Valenciana, Comunitat

Hospital Universitario Virgen Del Rocio, Sevilla, Not set

Hospital Clínico Universitario de Valladolid, Valladolid, Not set

Conditions: Chronic Migraine

Learn More ›

NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)

NCT05375812

Recruiting

Background: Gulf War illness (GWI) affects up to 210,000 U.S. veterans who served in the Middle East during the Gulf War in 1990-1991. Symptoms include fatigue, muscle and joint pain, forgetfulness, headaches, rashes, and sleep disturbances. Routine exams cannot determine the cause of GWI. Researchers need more information to understand this disease. Objective: This natural history study will look for differences in Gulf War veterans who experienced GWI and those who did not. Eligibility: G... Read More

Gender:

ALL

Ages:

Between 48 years and 70 years

Trial Updated:

06/25/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Gulf War Illness

Learn More ›

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

NCT05773274

Recruiting

This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus in patients who have previously received 177Lu-DOTATATE for midgut neuroendocrine tumor (NET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/25/2025

Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +27 locations

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

Mayo Clinic Hospital in Arizona, Phoenix, Arizona

UCHealth University of Colorado Hospital, Aurora, Colorado

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida

Mayo Clinic in Florida, Jacksonville, Florida

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida

UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida

Northwestern University, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois

Northwestern Medicine Cancer Center Delnor, Geneva, Illinois

UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois

University of Chicago Medicine-Orland Park, Orland Park, Illinois

Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois

University of Kentucky/Markey Cancer Center, Lexington, Kentucky

Henry Ford Hospital, Detroit, Michigan

Mayo Clinic in Rochester, Rochester, Minnesota

University of New Mexico Cancer Center, Albuquerque, New Mexico

University of Rochester, Rochester, New York

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

BCCA-Vancouver Cancer Centre, Vancouver, British Columbia

CancerCare Manitoba, Winnipeg, Manitoba

Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario

Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario

Conditions: Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor, Metastatic Midgut Neuroendocrine Tumor G1, Metastatic Midgut Neuroendocrine Tumor G2

Learn More ›

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

NCT06072482

Recruiting

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

06/25/2025

Locations: Orthopedic Physicians Alaska, Anchorage, Alaska +42 locations

Orthopedic Physicians Alaska, Anchorage, Alaska

Scottsdale Healthcare at Shea - HonorHealth, Scottsdale, Arizona

Southwest Kidney Institute, Surprise, Arizona

Medvin Clinical Research, Covina, California

Palo Alto Medical Foundation Fremont, Fremont, California

The Nephrology Group, Fresno, California

Providence Medical Foundation, Fullerton, California

Medvin Clinical Research, Menifee, California

Harbor University of California at Los Angeles Medical Center, Torrance, California

University of Colorado, Aurora, Colorado

Florida Kidney Physicians, Boca Raton, Florida

University of South Florida, Tampa, Florida

Emory University, Atlanta, Georgia

Lake Cumberland Rheumatology, New Albany, Indiana

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Dunes Clinical Research LLC, Sioux City, Iowa

University of Kentucky, Lexington, Kentucky

Johns Hopkins Bayview Medical Center, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Brigham and Womens Hospital, Boston, Massachusetts

Henry Ford Health System, Detroit, Michigan

University of Minnesota, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

Renown Rheumatology, Reno, Nevada

New York Nephrology Vasculitis and Glomerular Center, Albany, New York

Northwell Health, Great Neck, New York

Hospital For Special Surgery, New York, New York

East Carolina University Brody Outpatient Center, Greenville, North Carolina

Brookview Hills Research Associates Llc, Winston-Salem, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

The Ohio State University, Columbus, Ohio

Stat Research, Miamisburg, Ohio

Hightower Clinical, Oklahoma City, Oklahoma

Allegheny Health Network Cancer Institute at Mellon Pavilion, Pittsburgh, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Nephrology Associates Inc, East Providence, Rhode Island

Medical University of South Carolina, Charleston, South Carolina

West Tennessee Physicians' Alliance - Arthritis Clinic, Jackson, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Renal Disease Research Institute - Landry Office, Dallas, Texas

Nephrology Associates of Northern Virginia Inc, Fairfax, Virginia

Virginia Mason Medical Center, Seattle, Washington

Rheumatology and Pulmonary Clinic, Beckley, West Virginia

Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Learn More ›

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721

Recruiting

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

06/25/2025

Locations: Precision NextGen Oncology and Research Center, Beverly Hills, California +177 locations

Precision NextGen Oncology and Research Center, Beverly Hills, California

TOI Clinical Research, Cerritos, California

Cancer and Blood Specialty Clinic (CBSC), Los Alamitos, California

Valkyrie Clinical Trials, Los Angeles, California

PIH Health Hospital, Whittier, California

BRCR Medical Center Inc., Tamarac, Florida

Accellacare Duly, Plainfield, Illinois

Detroit Clinical Research Center, PC, Farmington Hills, Michigan

North Shore Hematology-Oncology Associates P.C. d/b/a New York Cancer & Blood Specialists, Shirley, New York

Gabrail Cancer Center Research, Canton, Ohio

Millennium Research and Clinical Development, LLC, Houston, Texas

Texas Oncology, P.A, San Antonio, Texas

Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia

Klinikum Klagenfurt am Woerthersee, Klagenfurt, Not set

Ordensklinikum Linz GmbH Elisabethinen, Linz, Not set

Hospital Santa Izabel, Santa Casa de Misericordia da Bahia, Salvador, Bahia

CRIO - Centro Regional Integrado de Oncologia, Fortaleza, Ceara

Centro de Pesquisas Clinicas em Oncologia (CPCO)/HECI, Cachoeiro de Itapemirim, Espirito Santo

Associacao Feminina de Educacao e Combate ao Cancer(AFECC) - Hospital Santa Rita, Vitoria, Espirito Santo

Cetus Oncologia S.A. Unidade Belo Horizonte, Belo Horizonte, Minas Gerais

Nucleo de Ensino Pesquisa e Inovacao Mario Penna, Belo Horizonte, Minas Gerais

Fundacao Sao Francisco Xavier - Hospital Marcio Cunha (HMC) - Unidade I, Ipatinga, Minas Gerais

Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner, Curitiba, Parana

Instituto de Cancer de Londrina - Hospital do Cancer de Londrina - HCL, Londrina, Parana

Hospital Tacchini, Bento Goncalves, Rio Grande Do Sul

Oncosite Centro De Pesquisa Clinica Em Oncologia, Ijui, Rio Grande Do Sul

Hospital da Cidade de Passo Fundo - HCPF, Passo Fundo, Rio Grande Do Sul

Unidade de Pesquisa Clinica em Oncologia Ltda (UPCO) (Clinica Lacks), Pelotas, Rio Grande Do Sul

Associacao dos Functionarios Publicos do Estado do Rio Grande do Sul - Hospital Ernesto Dornelles (H, Porto Alegre Rio Grande Do Sul, Rio Grande Do Sul

Hospital Bruno Born, Lajeado, RS

Centro de Pesquisa em Oncologia - Hospital Sao Lucas da PUC Rio Grande do Sul, Porto Alegre, RS

Centro de Oncologia de Santa Catarina Ltda / Supera Oncologia, Chapeco, Santa Catarina

CEPEN Centro de Pesquisa e Ensino em Saude de Santa Catarina, Florianopolis, Santa Catarina

Centro de Ensino e Pesquisa Reichow, Jardim Blumenau, Santa Catarina

Instituto Joinvillense de Hematologia e Oncologia SS Ltda - Clinica de Hematologia e Oncologia, Joinville, Santa Catarina

Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, Sao Paulo

Centro Oncologico Mogi das Cruzes, Mogi das Cruzes, Sao Paulo

Instituto Ribeiraopretano de Combate ao Cancer (IRPCc) - IRPCC, Ribeirao Preto, Sao Paulo

Faculdade de Medicina do ABC - Centro de Estudos e Pesqulsas de Hematologia e Oncologia, Santo Andre, Sao Paulo

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto - Hospital de Base de Sao Jose do R, Sao Jose do Rio Preto, Sao Paulo

Centro de Pesquisa Sao Lucas, Campinas, SP

Hospital Nossa Senhora das Gracas, Canoas, Not set

CIONC - Centro Integrado de Oncologia de Curitiba, Curitiba, Not set

Centro Integrado de Pesquisa em Oncologia - Hospital Nossa Senhora da Conceio, Porto Alegre, Not set

Instituto Nacional de Cancer (INCA), Rio De Janeiro, Not set

Hospital Sao Rafael, Salvador, Not set

Hospital Alemao Oswaldo Cruz (HAOC), Sao Paulo, Not set

Instituto Brasileiro de Controle do Cancer - IBCC Oncologia, Sao Paulo, Not set

University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski, Sofia, Sofiya-Grad

MHAT Dobrich AD, Dobrich, Not set

University Multiprofile Hospital for Active Treatment Sofiamed, Sofia, Not set

Centro de Investigaciones Clinicas Vina del Mar Ltda., Vina del Mar, Region De Valparaiso

Cdiem, Providencia, Region Metropolitana

Clinica Santa Maria, Santiago, Region Metropolitana

Centro de Investigacin de Enfermedades Respiratorias e Inmunologicas Limitada CIERI, Vina del Mar, Valparaiso

K2 Oncology, Santiago de Chile, Not set

Centro de Oncologa de Precisin, Santiago, Not set

Icegclinic Research and Care, Santiago, Not set

Centre Hospitalier Universitaire de Bordeaux - Hopital Saint - Andre, Bordeaux Cedex, Not set

Centre Hospitalier Universitaire de Limoges - Hopital Dupuytren, Limoges, Not set

Hopital Europeen Marseille, Marseille, Not set

Clinique Clementville-Gcs Centre De Cancerologie Du Grand Montpellier, Montpellier, Not set

Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau, Nimes, Not set

Centre Hospitalier Intercommunal Toulon La Seyne Sur Mer (C.H.I.T.S) - Hospital Font-Pre, Toulon, Not set

Clinique Teissier, Valenciennes, Not set

Hopital Robert Schuman, Vantoux, Not set

High Technology Hospital Medcenter LTD, Batumi, Not set

LLC Todua Clinic, Tbilisi, Not set

TIM -Tbilisi Institute of Medicine, Tbilisi, Not set

New Hospitals, Tbilisi, Not set

Medulla - Clinics And Medical Centers, Tbilisi, Not set

Studienzentrum Aschaffenburg, Aschaffenburg, Not set

Haematologie, Onkologie und Palliativmedizin, Tagesklinik Landshut, Landshut, Not set

FEK - Friedrich-Ebert-Krankenhaus Neumuenster GmbH, Neumuenster, Not set

Fondazione Irccs Ca' Granda Ospedale Maggioe Policlinico Di Milano, Milan, Not set

ASL Napoli 1 Centro-Ospedale del Mare, Napoli, Not set

AUSL Della Romagna - Ospedale S.Maria delle Croci, Ravenna, Not set

Japan Community Healthcare Organization Chukyo Hospital, Nagoya, Aichi

Funabashi Municipal Medical Center, Funabashi-shi, Chiba

Kyushu University Hospital, Fukuoka-shi, Fukuoka

Aso Iizuka Hospital, Iizuka-shi, Fukuoka

Japanese Red Cross Maebashi Hospital, Maebashi-shi, Gunma

Chugoku Central Hospital, Fukuyama city, Hiroshima

Hiroshima Prefectural Hospital, Hiroshima-city, Hiroshima

Asahikawa Medical University Hospital, Asahikawa City,, Hokkaido, Japan

Hyogo Prefectural Amagasaki General Medical Center, Amagasaki city, Hyogo

Nippon Medical School Musashikosugi Hospital, Kawasaki-shi, Kanagawa

Yokohama City University Hospital, Yokohama, Kanagawa

Yokosuka Kyosai Hospital, Yokosuka, Kanagawa

Social Welfare Organization Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital, Kumamoto city, Kumamoto

Osaki Citizen Hospital, Osaki, Miyagi

Miyazaki Prefectural Miyazaki Hospital, Miyazaki-shi, Miyazaki

Shinshu University Hospital, Matsumoto, Nagano

NHO Kinki Chuo Chest Medical Center, Sakai-city,, Osaka Japan

Kawaguchi Municipal Medical Center, Kawaguchi-shi, Saitama

Hamamatsu Medical Center, Hamamatsu City,, Shizuoka, Japan

Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka

Ome Medical Center, Ome-shi, Tokyo

Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do

Ajou University Hospital, Suwon-si, Gyeonggi-do

The Catholic University Of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi

Jeonbuk National University Hospital, Jeonju-si, Jeollabuk-do

Kyung Hee University Hospital, Seoul, Not set

Korea University Anam Hospital, Seoul, Not set

Kangbuk Samsung Hospital, Seoul, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

Hospital Sultanah Bahiyah, Alor Setar, Kedah

Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan

Sarawak General Hospital, Kuching, Sarawak

Hospital Canselor Tuanku Muhriz UKM, Cheras, Wilayah Persekutuan Kuala Lumpur

University of Malaya Medical Centre, Kuala Lumpur, Not set

Hospital III Goyeneche, Cercado, Arequipa

Instituto Nacional De Enfermedades Neoplasicas, Surquillo, Lima, Peru

Davao Doctors Hospital, Davao, Davao Del Sur

Asian Hospital And Medical Center, Muntinlupa, Metro Manila

Veterans Memorial Medical Center, Quezon City, Metro Manila

Riverside Medical Center Inc, Bacolod City, Negros Occidental

Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy, Bydgoszcz, Kujawsko-Pomorskie

Warminsko Mazurskie Centrum Chorob Pluc w Olsztynie, Olsztyn, Warminsko-mazurskie

Instytut MSF Sp. z o.o., Lodz, Not set

NZOZ Neuromed M. i M. Nastaj Sp.P., Lublin, Not set

Med-Polonia Sp. z o.o., Poznan, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o., Slupsk, Not set

Clincial Centre of Serbia, Belgrade, Not set

University Clinical Centre of Kragujevac, Kragujevac, Not set

Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Not set

Hospital General Universitario de Elche, Alicante, Not set

UOMI Cancer Center-Clinica Tres Torres, Barcelona, Not set

Hospital Quironsalud Barcelona, Barcelona, Not set

Complejo Hospitalario de Jaen (University Hospital Ciudad De Jaen), Jaen, Not set

Hospital Clinico San Carlos, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario Fundacion Alcorcon, Madrid, Not set

Hospital Quironsalud Malaga, Malaga, Not set

Hospital De Mataro, Mataro, Not set

Hospital Universitario Central de Asturias, Oviedo, Not set

Hospital Universitario Nuestra Senora De Valme, Sevilla, Not set

Hospital Universitario Virgen del Rocio, Seville, Not set

Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulev, Valencia, Not set

Hospital Quironsalud Valencia, Valencia, Not set

Tri-Service General Hospital, Neihu, Taipei

National Taiwan University Hospital (NTUH), Taipei, Zhongzheng Dist

Dalin Tzu chi General Hospital - Buddhist Tzu chi Medical Foundation, Chia-Yi, Not set

National Taiwan University Hospital Yun-Lin Branch, Douliu City, Not set

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Not set

Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital, Kaohsiung County, Not set

Taipei Medical University (TMU) - Shuang Ho Hospital (SHH), New Taipei City, Not set

Chung Shan Medical University Hospital, Taichung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

Taipei Veterans General Hospital, Taipei, Not set

Mahidol University - Siriraj Hospital - Siriraj Clinical Research Center (SICRC), Bangkoknoi, Bangkok

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Muang, Chiang Mai

Chiangrai Prachanukroh Hospital, Muang, Chiang Rai

Chulabhorn Hospital, Talat Bang Khen, Lak Si

Naresuan University Hospital, Muang, Phitsanulok

Prince Of Songkla Hospital, Prince Of Songkhla University, Hat-Yai, Songkhla

Vajira Hospital, Bangkok, Not set

King Chulalongkorn Memorial Hospital, Chulalongkom University, Bangkok, Not set

Gulhane Training and Research Hospital, Kecioeren, Ankara

Gazi University Faculty of Medicine, Yenimahalle, Ankara

Trakya University Faculty of Medicine, Iskender, Edirne

Ondokuz Mayis University Health Practice and Research Hospital, Atakum, Samsun

Medical Park Seyhan Hospital, Adana, Not set

Adana City Training and Research Hospital, Adana, Not set

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Not set

Memorial Ankara Hospital, Ankara, Not set

Liv Hospital Ankara, Ankara, Not set

Ankara Bilkent City Hospital, Ankara, Not set

Uludag University Medical Faculty, Bursa, Not set

Medical Point Gaziantep Hospital, Gaziantep, Not set

Bezmialem Foundation University Medical Faculty, Istanbul, Not set

Istanbul Medeniyet University Medical Faculty, Istanbul, Not set

Necmettin Erbakan University Meram Medical Faculty, Konya, Not set

Sakarya Universitesi Tip Fakultesi, Sakarya, Not set

Namik Kemal Universitesi Hastanesi, Tekirdag, Not set

Nottingham University Hospitals NHS Trust - Nottingham City Hospital, Nottingham, Nottinghamshire

Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Learn More ›

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT06503146

Recruiting

Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in certain cancer cells. \[18F\]FAPI-74 is a new tracer-a substance that is injected into a person s body before an imaging scan. Researchers believe that \[18F\]FAPI-74 may be able to highlight FAP enzymes more effectively than approved tracers. If so, the new tracer would make it easier to find FAP-positive tumors in the body. Objective: To see if \[18F\]FAPI-74 PET scans are as good or better than oth... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

06/25/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma, Gastric Cancer, Bladder Cancer, Hepatocellular Carcinoma, Pheochromocytoma, Ovarian Cancer

Learn More ›

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

NCT06675929

Recruiting

This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of this study is to find out how well a medicine called BI 770371 is tolerated. Participants are put into 2 groups by chance. One group gets BI 770371 as an infusion into a vein and the other group gets placebo as an infusion into a vein. Placebo infusions look like BI 770371 infusions but do not contain any medicine. Participants get an infusion ever... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

06/25/2025

Locations: Southern California Research Center, Coronado, California +11 locations

Conditions: Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)

Learn More ›

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

NCT06807463

Recruiting

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease. The expected trial duration per participant is approximately 86 weeks.

Gender:

ALL

Ages:

Between 18 years and 64 years

Trial Updated:

06/25/2025

Locations: Teva Investigational Site 12131, Colorado Springs, Colorado +11 locations

Conditions: Celiac Disease

Learn More ›

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697

Recruiting

Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers are developing a new treatment that collects a person s own immune cells (T cells); the T cells are genetically modified to target and kill tumor cells with high levels of MSLN. Objective: To test a new treatment (TNh... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

06/25/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Ovarian Neoplasms, Lung Neoplasms, Thymus Neoplasms, Colonic Neoplasms

Learn More ›